DB:1HB1

Stock Analysis Report

Executive Summary

Heat Biologics, Inc., a biopharmaceutical company, focuses on developing immunotherapies to activate patient’s immune system against cancer through T-cell activation.


Snowflake Analysis

Adequate balance sheet and overvalued.

Share Price & News

How has Heat Biologics's share price performed over time and what events caused price changes?


Latest Share Price and Events

Stable Share Price: 1HB1's share price has been volatile over the past 3 months.


Market Performance


7 Day Return

-3.8%

1HB1

11.2%

DE Biotechs

7.3%

DE Market


1 Year Return

-53.9%

1HB1

-5.1%

DE Biotechs

-17.7%

DE Market

Return vs Industry: 1HB1 underperformed the German Biotechs industry which returned -5.1% over the past year.

Return vs Market: 1HB1 underperformed the German Market which returned -17.5% over the past year.


Shareholder returns

1HB1IndustryMarket
7 Day-3.8%11.2%7.3%
30 Day82.9%-5.3%-17.9%
90 Day34.6%-21.9%-25.8%
1 Year-53.9%-53.9%-4.9%-5.1%-15.1%-17.7%
3 Year-93.9%-93.9%17.7%16.5%-18.7%-25.6%
5 Year-99.1%-99.1%-5.1%-7.5%-17.7%-29.0%

Price Volatility Vs. Market

How volatile is Heat Biologics's share price compared to the market and industry in the last 5 years?


Simply Wall St News

No news available

Valuation

Is Heat Biologics undervalued compared to its fair value and its price relative to the market?

1.17x

Price to Book (PB) ratio


Share Price vs. Fair Value

Below Fair Value: Insufficient data to calculate 1HB1's fair value to establish if it is undervalued.

Significantly Below Fair Value: Insufficient data to calculate 1HB1's fair value to establish if it is undervalued.


Price To Earnings Ratio

PE vs Industry: 1HB1 is unprofitable, so we can't compare its PE Ratio to the Biotechs industry average.

PE vs Market: 1HB1 is unprofitable, so we can't compare its PE Ratio to the German market.


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate 1HB1's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: 1HB1 is good value based on its PB Ratio (1.2x) compared to the DE Biotechs industry average (3.6x).


Next Steps

Future Growth

How is Heat Biologics forecast to perform in the next 1 to 3 years based on estimates from 3 analysts?

-10.7%

Forecasted annual earnings growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: 1HB1 is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: 1HB1 is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: 1HB1 is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: 1HB1's revenue is expected to decline over the next 3 years (-59.8% per year).

High Growth Revenue: 1HB1's revenue is forecast to decline over the next 3 years (-59.8% per year).


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: Insufficient data to determine if 1HB1's Return on Equity is forecast to be high in 3 years time


Next Steps

Past Performance

How has Heat Biologics performed over the past 5 years?

-3.3%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: 1HB1 is currently unprofitable.

Growing Profit Margin: 1HB1 is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: 1HB1 is unprofitable, and losses have increased over the past 5 years at a rate of -3.3% per year.

Accelerating Growth: Unable to compare 1HB1's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: 1HB1 is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (8.7%).


Return on Equity

High ROE: 1HB1 has a negative Return on Equity (-137.4%), as it is currently unprofitable.


Next Steps

Financial Health

How is Heat Biologics's financial position?


Financial Position Analysis

Short Term Liabilities: 1HB1's short term assets ($15.8M) exceed its short term liabilities ($4.8M).

Long Term Liabilities: 1HB1's short term assets ($15.8M) exceed its long term liabilities ($3.5M).


Debt to Equity History and Analysis

Debt Level: 1HB1 is debt free.

Reducing Debt: 1HB1 has no debt compared to 5 years ago when its debt to equity ratio was 8.4%.


Balance Sheet

Inventory Level: 1HB1 has a low level of unsold assets or inventory.

Debt Coverage by Assets: Insufficient data to determine if 1HB1's debt is covered by short term assets.


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: 1HB1 has less than a year of cash runway based on its current free cash flow.

Forecast Cash Runway: 1HB1 has less than a year of cash runway if free cash flow continues to reduce at historical rates of -11.3% each year


Next Steps

Dividend

What is Heat Biologics's current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

Notable Dividend: Unable to evaluate 1HB1's dividend yield against the bottom 25% of dividend payers, as the company has not reported any payouts.

High Dividend: Unable to evaluate 1HB1's dividend yield against the top 25% of dividend payers, as the company has not reported any payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if 1HB1's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if 1HB1's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of 1HB1's dividend in 3 years as they are not forecast to pay a notable one for the German market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

2.8yrs

Average management tenure


CEO

Jeff Wolf (56yo)

11.58s

Tenure

US$2,405,032

Compensation

Mr. Jeffrey Alan Wolf, also known as Jeff, J.D., is the Chief Executive Officer and President of Heat Biologics, Inc. since August 2008 and served as its Treasurer and Secretary. Mr. Wolf Co-Founded Pelica ...


CEO Compensation Analysis

Compensation vs Market: Jeff's total compensation ($USD2.41M) is above average for companies of similar size in the German market ($USD432.27K).

Compensation vs Earnings: Jeff's compensation has increased whilst the company is unprofitable.


Leadership Team

NamePositionTenureCompensationOwnership
Jeffrey Wolf
Founder11.58yrsUS$2.41m6.83% $2.1m
William Ostrander
VP of Finance & Secretary0.50yrUS$266.85kno data
Jeff Hutchins
Chief Scientific Officer & COO2.75yrsUS$932.14k0.25% $75.4k
Justin Stebbing
Chief Medical Advisor and Member of Scientific & Clinical Advisory Boardno datano datano data
George Peoples
Chief Medical Advisor2.92yrsno datano data

2.8yrs

Average Tenure

56yo

Average Age

Experienced Management: 1HB1's management team is considered experienced (2.8 years average tenure).


Board Members

NamePositionTenureCompensationOwnership
Jeffrey Wolf
Founder11.58yrsUS$2.41m6.83% $2.1m
Justin Stebbing
Chief Medical Advisor and Member of Scientific & Clinical Advisory Boardno datano datano data
John K. Prendergast
Lead Independent Director3.5yrsUS$539.00k1.22% $368.6k
John Monahan
Independent Director10.33yrsUS$201.90k0.00090% $272.1
Llew Keltner
Member of Scientific & Clinical Advisory Boardno datano datano data
Roger Cohen
Member of Scientific & Clinical Advisory Boardno datano datano data
Gary Acton
Member of Scientific & Clinical Advisory Boardno datano datano data
Robert Negrin
Member of Scientific Advisory Board2.42yrsno datano data
Edward Smith
Independent Director9.33yrsUS$212.90k0.060% $18.2k
Robert Levy
Member of Scientific Advisory Board2.42yrsno datano data

6.4yrs

Average Tenure

62.5yo

Average Age

Experienced Board: 1HB1's board of directors are considered experienced (6.4 years average tenure).


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Ownership Breakdown

Dilution of Shares: Shareholders have been substantially diluted in the past year, with total shares outstanding growing by 160.3%.


Top Shareholders

Company Information

Heat Biologics, Inc.'s company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Heat Biologics, Inc.
  • Ticker: 1HB1
  • Exchange: DB
  • Founded: 2008
  • Industry: Biotechnology
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: US$33.528m
  • Listing Market Cap: US$30.239m
  • Shares outstanding: 57.42m
  • Website: https://www.heatbio.com

Number of Employees


Location

  • Heat Biologics, Inc.
  • 627 Davis Drive
  • Suite 400
  • Morrisville
  • North Carolina
  • 27560
  • United States

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
HTBXNasdaqCM (Nasdaq Capital Market)YesCommon StockUSUSDJul 2013
1HB1DB (Deutsche Boerse AG)YesCommon StockDEEURJul 2013

Biography

Heat Biologics, Inc., a biopharmaceutical company, focuses on developing immunotherapies to activate patient’s immune system against cancer through T-cell activation. The company’s T-cell activation platform, includes two variations for intradermal administration, such as immune pan-antigen cytotoxic therapy, an allogenic cell-based, T-cell-stimulating platform that functions as an immune activator to stimulate and expand T-cells; and combination pan-antigen cytotoxic therap, a dual-acting immunotherapy, which delivers antigen driven T-cell activation and specific co-stimulation in a single product. It is developing HS-110, which is in phase II clinical trials to treat patients with advanced non-small cell lung cancer. Its preclinical stage products include HS-130 for the treatment of advanced solid tumors; PTX-35, a humanized affinity matured monoclonal antibody, which is a functional agonist of human TNFRSF25 signaling; and PTX-45, a human TL1A-Ig fusion protein that acts as an agonist of TNFRSF25 signaling. Heat Biologics, Inc. has a collaboration with the University of Miami to develop a coronavirus COVID-19 point-of-care diagnostic test to deliver results on a paper strip in under 30 minutes. The company was founded in 2008 and is headquartered in Morrisville, North Carolina. 


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2020/03/29 23:23
End of Day Share Price2020/03/27 00:00
Earnings2019/09/30
Annual Earnings2018/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.